BRD4 inhibitors have demonstrated promising results in both preclinical and clinical studies against various cancer types, including leukemia, lymphoma, and solid tumors such as breast, lung, and prostate cancers [22,23]. The gene discussed is BRD4; the disease is lymphoma.